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Abstract. Leptomeningeal metastasis (LM) is an uncommon 
presentation of relapse in breast cancer, which is associated 
with poor clinical outcomes and poor prognosis. Notably, 
LM most commonly occurs in breast cancer. The aim of 
the present review was to investigate the occurrence of LM 
as the primary presentation of relapse following remission 
in breast cancer patients and to determine whether specific 
histological subtypes are predisposed to meningeal metas-
tases. In addition, the present review evaluated whether 
patients presenting with LM as the primary site of relapse 
exhibit differences in survival when compared with patients 
exhibiting metastasis to other sites. Cross-sectional studies 
have demonstrated that LM is commonly associated with 
other sites of distant metastasis including lung, liver and 
bone metastases. The histological breast cancer subtype most 
commonly associated with LM was invasive lobular carci-
noma, while triple-negative breast cancer patients appear to 
be predisposed to the development of LM when considering 
the overall prevalence of histological breast cancer subtypes. 
At present, data regarding LM as the primary site of relapse 
are limited due to its rarity as the first site of metastasis in 
breast cancer. Case-controlled studies are required to investi-
gate the incidence of LM as the primary site of recurrence in 
breast cancer patients as this would enable treatment standard-
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1. Introduction
Leptomeningeal metastasis (LM) occurs when solid tumour 
cells diffusely metastasize to the meninges within the central 
nervous system (CNS) (1). It is a manifestation of metastatic 
disease whereby tumour cells spread through the subarach-
noid space (1). LM occurs in 4-7% of patients with solid 
tumours and is common in breast cancer, lung cancer and 
malignant melanoma (1). The highest rates of LM are observed 
in melanoma and small lung cancer, with incidence rates of 
23 and 11%, respectively (2,3). LM occurs in ≤5% of patients 
diagnosed with breast cancer (4). Previous studies have reported 
that the frequency of triple-negative (TN) breast cancer among 
LM patients ranges between 21 and 40.5% (5-7). The annual 
age-standardized incidence rates of LM are 78 and 90 cases 
per 100,000 women in Western Europe and North America, 
respectively (8). Considering this high incidence, breast cancer 
patients constitute the majority of cases diagnosed with LM (9). 
Furthermore, LM usually occurs after diagnosis of distant 
metastasis to other sites. Concurrent lung and liver metastases 
have been reported at a frequency of 27% in each organ in breast 
cancer patients with LM. Brain and bone metastases have also 
been reported to occur in 49 and 51% of breast cancer patients 
with LM, respectively (10). Survival in patients diagnosed 
with LM is poor with an estimated median survival time of 
4.9 months (11). Current treatment recommendations for LM 
patients with modest tumor burden include intrathecal chemo-
therapy, radiation therapy to disease obstructing cerebrospinal 
fluid flow and strategies to decrease intracranial pressure (12).
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The primary aim of the present review was to investi-
gate the frequency of LM as the primary presentation of 
distant metastasis in breast cancer patients, as reported 
in the current literature, and to determine whether such 
patients exhibit different survival outcomes when compared 
with LM patients that exhibit metastasis to other sites. The 
secondary aim was to investigate the association between 
LM incidence and specific histological and biological 
subtypes of breast cancer and their prognostic significance.
2. Methodology
Medical databases including Medline (http://www.medline.
com/), Embase (https://www.embase.com) and PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) were searched to 
retrieve articles published between 2004 and 2015 for the 
present literature review. The keywords used included ‘breast 
cancer’, ‘leptomeningeal carcinomatosis’, ‘leptomeninges’, 
‘metastasis’, ‘clinical outcomes’ and ‘relapse’. Keywords 
were entered using appropriate database selection headings 
in MeSH or Emtree. Prospective and retrospective studies 
that included patients with LM as a presentation of relapse in 
breast cancer were selected. Case reports and case series were 
excluded. Only studies published in English were reviewed.
3. Frequency of LM as the first presentation of distant me-
tastasis
The majority of studies conducted on LM in breast cancer 
included patients diagnosed clinically and pathologically with 
LM as a complication of breast cancer (Table I). Such patients 
were followed up prospectively following diagnosis with 
the aim to identify prognostic markers of survival (7,11). No 
prospective studies that determined the absolute rate of LM 
as the only presentation of distant metastasis in breast cancer 
were identified.
A study by Niwińska et al (7) evaluated a cohort of 
118 consecutive breast cancer patients treated for LM 
between 1999 and 2009. At presentation, 25% (29/118) of 
patients presented with metastasis of the leptomeninges as 
the first presentation of metastatic disease (7). However, this 
study was limited as the authors did not mention whether 
the 29 patients were previously treated for metastasis. In a 
study by Torrejón et al (13), 13.2% (5/38) of breast cancer 
patients exhibited LM as the first presentation of metastatic 
disease (13). Although this was not the primary outcome 
of the study and despite the small cohort size, it identified 
patients with LM indicating that this was the primary presen-
tation of metastasis.
Lara-Medina et al (10) reported patient characteris-
tics at the time of diagnosis of LM: At diagnosis of LM, 
8/61 (13.1%) exhibited no systemic disease, while 8/49 
(16.3%) of patients exhibited controlled systemic disease 
and 33/49 (67.3%) exhibited systemic disease (10). Although 
the study did not report whether patients were in remission 
prior to presenting with LM, the incidence rate was similar 
to that reported by Niwińska et al (7). Niwińska et al (7) also 
reported the concurrent occurrence of distant metastases 
in breast cancer patients: 48% of patients exhibited bone 
metastases, 38% exhibited metastases of the brain paren-
chyma, 36% exhibited lung metastases and 25% exhibited 
liver metastases (7). These results are consistent with the 
hypothesis that the majority of breast cancer patients who 
exhibit LM present with systemic disease at diagnosis, 
with 25% of patients exhibiting LM as the only site of 
distant metastasis. Previous studies have reported that in 
9-15% of breast cancer patients, LM is the first presenta-
tion of metastasis (11,14). However, data that demonstrates 
the frequency of LM as the first presentation of relapse 
following breast cancer treatment is limited and thus, only a 
comparative assessment of such studies was performed.
4. Predilection of histological and biological breast cancer 
subtypes for meningeal metastases
Metastasis to the leptomeninges is most common in patients 
diagnosed with the invasive lobular carcinoma histological 
subtype of breast cancer (5,15). While the rate of lobular 
carcinoma varies between 17 and 28% among patients initially 
diagnosed with breast cancer, studies have revealed that ≤35% 
of patients with LM exhibit lobular carcinoma (Table II). This 
indicates that metastasis to the meninges is most common in 
this histological subtype of breast cancer (7). However, only 
7% of breast patients with brain parenchymal metastasis 
Table I. Summary of previous literature regarding median age at diagnosis of leptomeningeal metastases and median survival 
time from diagnosis in breast cancer patients.
 Total LM Median age at Median survival time
First author, year patient cohort, n diagnosis, years (months) (Ref.)
Gauthier H et al, 2010   91 53.0 4.5  (5)
Yust-Katz S et al, 2013 103 49.2 4.2  (6)
Niwińska A et al, 2013 118 49.0 4.2  (7)
Lara-Medina F et al, 2012   49 42.4 1.6 (10)
Meattini I et al, 2012   33 46.7 4.9 (11)
Torrejón D et al, 2013   38 54.8 2.6 (13)
de Azevedo CR et al, 2011   60 46.0 3.3 (14)
LM, leptomeningeal metastasis.
  
ONCOLOGY LETTERS  12:  779-782,  2016 781
exhibit lobular carcinoma (16). This specific predisposition 
exhibited by lobular cancer to metastasize to the meninges 
has been attributed to changes in cell adhesion molecules (17). 
Autopsy data from metastatic breast cancer patients has 
demonstrated that the estimated incidence of LM in infiltrating 
lobular breast carcinoma is 14% compared with 1% in cases of 
infiltrating ductal breast carcinoma (18).
Breast cancer subtypes are considered to exhibit partic-
ular patterns of metastasis, which leads to distinct survival 
rates following relapse (5). Previous studies have analysed 
the incidence and prognostic implications of LM in the 
following four molecular subtypes: Luminal A [estrogen 
receptor (ER)/progesterone receptor (PR) positive, human 
epidermal growth factor receptor 2 (HER2) negative]; 
luminal B (ER/PR positive, HER2 positive); HER2 positive 
(ER/PR negative, HER2 positive); and TN (ER/PR nega-
tive, HER2 negative) (7,10,13). In a cohort of 99 patients 
with LM, 40.5% patients were classified as TN, 37.5% as 
luminal A, 14% as HER2 positive and 8% luminal B, which 
indicates that metastasis to the meninges is most common in 
patients exhibiting TN breast cancer (7). When comparing 
the frequency of molecular subtypes in LM with that in the 
whole breast cancer population, the results indicate that 
TN patients exhibit a higher predisposition for LM than 
the luminal A subtype. Two previous studies reported TN 
breast cancer frequencies of 39 and 21% in cohorts of 61 and 
91 breast cancer patients, respectively (5,10).
Patients exhibiting HER2 positive subtypes generally 
exhibit metastasis to the brain parenchyma; however, metastasis 
to the leptomeninges is less common (5,16). The most common 
molecular subtype of lobular carcinoma with dissemination 
to the leptomeninges was luminal A, as observed in >50% of 
the lobular carcinoma patients. Notably, in ductal carcinoma 
patients with LM, at initial diagnosis the four main biological 
subtypes were equally represented (7). Although studies have 
classified patients with LM into histological and molecular 
subtypes, few studies have investigated the molecular subtypes 
in patients exhibiting LM as the first presentation of distant 
metastasis.
5. Survival and prognosis
Various prognostic markers, including age at diagnosis, tumor 
histology, histologic grade and biomarker receptor status (ER, 
PR and HER2), have been evaluated, however, their value in 
guiding the management of cancer remains controversial. The 
most important prognostic factor for breast cancer patients 
diagnosed with LM. remains the performance status at 
the time of diagnosis (19). In a previous study, multivariate 
analysis revealed that a Karnofsky performance status of 
≥70 vs. <70 was significantly associated with increased 
survival (7,20). Systemic therapy is also a critical factor that 
influences survival. It is hypothesized that thick LM (lesions 
>3 mm) is well-penetrated by systemic therapy as opposed 
to intrathecal therapy due to the abundant vasculature. Intra-
thecal chemotherapy only achieves 2-3 mm penetration into 
meningeal metastases (7). Additional factors associated with 
poor outcome during treatment include multiple-fixed neuro-
logical deficits (21), bulky CNS disease (22), abnormalities 
in cerebrospinal fluid flow (23) and diffusely disseminated 
cancer that is unresponsive to systemic chemotherapy (21).
In a previous study, multivariate analysis revealed no signifi-
cant differences in survival between histological and biological 
breast cancer subtypes (7). Notably, the absence of PR expression 
in primary breast cancer has been reported as a poor prognostic 
factor (10). However, this study had a number of limitations: The 
study was retrospective and certain results regarding prognostic 
factors were not consistent with previously published literature. 
To date, no studies have investigated the association between 
patients presenting with LM as the primary site of recurrence 
and improved survival and prognostic outcomes.
The significance of such prognostic factors remains unclear, 
as the previous studies discussed were retrospective and included 
non-randomised participants. Furthermore, marked variability 
in the median age at diagnosis of patients was evident between 
studies. Thus, the context of such results must be considered. 
Therefore, future longitudinal and prospective studies, which 
include multivariate analysis, are required to investigate the 
associations between prognostic factors and clinical outcomes.
Table II. Summary of previous literature regarding the histological and molecular subtypes of breast cancer patients with LM.
 Histological 
 subtype (%) Molecular subtype (%)
 ---------------------------------  ----------------------------------------------------------------------------------------------------------------
     ER+ and/
First author, year IDC ILC ER+ PR+ or PR+ HER2+ TN (Ref.)
Gauthier H et al, 2010 63 28 70 44 74 10 21  (5)
Yust-Katz S et al, 2013 78.2 21.8 ND ND 55.3 47.4 22.8  (6)
Niwińska A et al, 2013 59 35 42 ND ND 19 40.5  (7)
Lara-Medina F et al, 2012 76 14 20 27 ND 20 39 (10)
Meattini I et al, 2012 63.6 36.4 ND ND 60.6 ND ND  (11)
Torrejón D et al, 2013 ND ND 34.2 26.3 ND 26.3 23.7 (13)
de Azevedo CR et al, 2011 78.3 21.6 51.7 43.3 ND 15 30 (14)
ND, no data available; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER+, estrogen receptor positive; PR+, progesterone 
receptor positive; HER2+, human epidermal growth factor receptor 2 positive; TN, triple-negative.
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6. Conclusion
Of all solid tumour types, LM most commonly occurs in 
breast cancer (1). LM most commonly occurs at an advanced 
stage of disease and occurs as the primary presentation of 
metastatic disease in 9-25% of patients diagnosed with breast 
cancer. LM most commonly occurs in patients histologically 
diagnosed with lobular carcinoma, and patients exhibiting 
TN breast cancer appear to exhibit a predisposition for LM. 
Although few studies have investigated LM as the primary 
site of relapse in breast cancer, anecdotal evidence and case 
reports suggest that such patients exhibit improved overall 
survival compared with patients that exhibit distant metastasis 
at other sites (24). The main factors that appear to affect prog-
nosis and treatment outcomes include the location of distant 
metastasis, response to treatment and performance status (7). 
Previous studies have suggested that histological subtypes 
and receptor expression may have less prognostic significance 
than the aforementioned factors (7,10). To further evaluate this 
hypothesis, case-controlled studies are required that investi-
gate breast cancer patients presenting with LM as the primary 
site of recurrence. Patients with the same histological subtype 
of breast cancer and performance status should be treated 
uniformly to establish a standard care. At present, multimodal 
chemotherapy and radiotherapy treatment for breast cancer 
should be individualized according to the patient's perfor-
mance status and response to treatment.
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